OncRef

Clinical Trial: NCT03587662

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:M.D. Anderson Cancer Center
Information Provided By:M.D. Anderson Cancer Center
Last Update Posted:2026-08-11

Study Overview

Brief Summary

This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating patients with kidney cancer that has spread to other places in the body (locally advanced or metastatic). Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib, gemcitabine, and doxorubicin may work better in treating patients with kidney cancer.

Official Title

Phase II Trial of Ixazomib Combined With Gemcitabine and Doxorubicin in Patients With Renal Medullary Carcinoma

Conditions

Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8

Intervention / Treatment

  • Drug: Doxorubicin
  • Drug: Doxorubicin Hydrochloride
  • Drug: Gemcitabine
  • Drug: Gemcitabine Hydrochloride
  • Drug: Ixazomib
  • Drug: Ixazomib Citrate

Other Study ID Numbers

  • 2018-0065
  • NCI-2018-01292
  • 2018-0065

Start Date (Actual)

2018-08-17

Primary Completion Date (Actual)

2026-08-04

Study Completion Date (Actual)

2026-08-04

Enrollment (Actual)

30

Study Type

Interventional

Phase

Phase 2